C-Rad ABLTS:0R44 83 Net Margin % is 10.70% as of Mar. 2026, which is 139% above its 10-year median of 4.48. GuruFocus rates LTS:0R44 with a GF Score™ of 83/100 and a GF Value™ of kr33.44 (Fairly Valued). The stock has 4 warning signs investors should review. Among 817 Medical Devices & Instruments companies, C-Rad AB ranks better than 64.26% on this metric.
Net margin is calculated as Net Income divided by its Revenue. C-Rad AB's Net Income for the
three
months ended in Mar. 2026 was kr11.2 Mil. C-Rad AB's Revenue for the
three
months ended in Mar. 2026 was kr104.7 Mil. Therefore, C-Rad AB's net margin for the quarter that ended in Mar. 2026 was 10.70%.
The historical rank and industry rank for C-Rad AB's Net Margin % or its related term are showing as below:
LTS:0R44'
s Net Margin % Range Over the Past 10 Years
Min: -37.76 Med: 4.48 Max: 12.04
Current: 6.94
LTS:0R44's Net Margin % is ranked better than 64.26% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs LTS:0R44: 6.94
C-Rad AB (LTS:0R44) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
C-Rad AB Net Margin % Related Terms
C-Rad AB Net Margin % Historical Data
* Premium members only.
The historical data trend for C-Rad AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R44 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, C-Rad AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where C-Rad AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
C-Rad AB (LTS:0R44) has a Net Margin % of 10.70% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on C-Rad AB and its competitors. This is 139% above median its historical median of 4.48. According to the industry distribution chart, C-Rad AB ranks #292 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 35.7%.
Is C-Rad AB's Net Margin % too high?
C-Rad AB's current Net Margin % of 10.70% is 139% above median its 10-year median of 4.48. The Medical Devices & Instruments industry median Net Margin % is 2.09. C-Rad AB's value of 10.70% is 412% above this industry median. Based on the distribution chart, C-Rad AB ranks #292 out of 817 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, C-Rad AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #292 out of 817 companies for Net Margin %. This puts C-Rad AB in the upper half of its industry. The industry median Net Margin % is 2.09. C-Rad AB's value of 10.70% is 412% above this benchmark. While the company's 10-year median is 4.48 vs. the industry median of 2.09, C-Rad AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current Net Margin % of 10.70% is 412% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current Net Margin % is 10.70%, which is 139% above median its own 10-year median of 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.44, compared to a current price of kr35.90 — trading 7.4% above its estimated fair value. The current Net Margin % is 10.70%, which is 139% above median its 10-year median of 4.48 and 412% above the Medical Devices & Instruments industry median of 2.09. C-Rad AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current Net Margin % is 10.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr35.90 is trading 7.4% above its estimated GF Value™ of kr33.44.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
Net Margin %: 10.70% (139% above median its 10-year median of 4.48)
GF Value™: kr33.44 vs. price of kr35.90 (7.4% above fair value)
Industry Position: 412% above the Medical Devices & Instruments median (#292 of 817)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
83GF Score
Get the complete analysis for LTS:0R44
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
